Menu

US Court Issues Injunction Against Open-Access Publisher OMICS

The Federal Trade Commission won an initial ruling against the India-based publisher for allegedly misleading researchers and for misrepresenting journal impact factors and editorial boards. 

Nov 27, 2017
Katarina Zimmer

ISTOCK, SEZERYADIGARLast week (November 22), the Federal Trade Commission (FTC) announced that it won an initial court ruling against OMICS, a publisher of open-access journals. The preliminary injunction stems from a complaint filed in August 2016 by the FTC against OMICS CEO Srinubabu Gedela, and affiliated companies ImedPub and Conference Series, alleging that they published articles without standard peer review, misrepresented numerous scientists as editors, and made multiple deceptive claims towards researchers.

According to the complaint, OMICS did not disclose to researchers that they would have to pay extraordinarily high publishing fees until articles were accepted for publication. The company also failed to disclose that it calculated its journal impact factors in an unorthodox fashion, FTC claims, and falsely stated that its journals are indexed by federal research databases such as the National Institutes of Health’s PubMed and Medline services.

“The defendants in this case used false promises to convince researchers to submit articles presenting work that may have taken months or years to complete, and then held that work hostage over undisclosed publication fees ranging into the thousands of dollars,” Jessica Rich, Director of the FTC’s Bureau of Consumer Protection, says in a press release. “It is vital that we stop scammers who seek to take advantage of the changing landscape of academic publishing.”

Chief judge in the case, Gloria Navarro of the District Court of Nevada, wrote that the evidence supplied by the FTC is “sufficient to support a preliminary conclusion that Defendants made misrepresentations regarding their journal publishing.”

The defendants will still be able to publish their journals, but they have been ordered to remove misleading claims from their websites, according to the Toronto Star. Navarro found the ruling necessary, writing that “absent such an injunction, the Court finds it likely that Defendants will continue to engage in deceptive practices.”

OMICS Group is an India-based publisher, and claims to put out more than 700 peer-reviewed journals on its website. An investigation by the Toronto Star/CTV News found last year that OMICS had purchased multiple reputable medical journals throughout Canada, which raised concerns among scientists that they were being “hijacked” to publish “junk science for profit.” OMICS had been included on the now-defunct list of predatory publishers compiled by Jeffrey Beall, a librarian at the University of Colorado Denver (archived version).

OMICS CEO Gedela tells the Star after learning of the injunction that he did not believe the allegations being made against the company. The “FTC made allegations based on ‘fake news,’” he says. “We are pretty sure FTC will not be able to prove any of the allegations against us.”

Gregory Ashe, a senior attorney for the FTC’s division of financial practices, tells Retraction Watch that the lawsuit was not intended to regulate the journals or their content, but to combat the deceptive practices. “This is certainly our message to the academic world that, we are monitoring and on the lookout for predatory publishers.”

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN Ltd are pleased to announce the commercial licensing of CRISPR-Cas9 gene-editing technology from Broad Institute of MIT and Harvard in the USA, to develop human cell disease models to support preclinical metabolic disease therapeutic programmes.